Romosozumab is named as an intervention in 2 current clinical trials in our China, UK and USA registers. None are recruiting at the moment. The most common phase is Phase 3. The sponsor with the most trials is Amgen (1). The most-studied condition is Osteogenesis Imperfecta.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Compare the Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of SAL023 and Italy-Manufactured Evenity in Healthy Subjects
NCT07384104 · ClinicalTrials.gov ↗ · Osteoporosis
|
Phase 1 | By invitation | Shenzhen Salubris Pharmaceuticals Co., Ltd. | China |
|
Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta
NCT05972551 · ClinicalTrials.gov ↗ · Osteogenesis Imperfecta
|
Phase 3 | Active, closed | Amgen | UK, USA, China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Amgen | 1 |
| Shenzhen Salubris Pharmaceuticals Co., Ltd. | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 0 |
| Clinical trials in UK | 1 | 0 |
| Clinical trials in USA | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our China, UK and USA registers name Romosozumab as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Not at the moment. None of the 2 trials in our registers is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.
Amgen (1) and Shenzhen Salubris Pharmaceuticals Co., Ltd (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Romosozumab works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Romosozumab works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Romosozumab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.